このエントリーをはてなブックマークに追加
ID 52703
Sort Key
7
タイトル(別表記)
Induction therapy followed by surgery for non small-cell lung cancer
フルテキストURL
Thumnail 126_103.pdf 473 KB
著者
豊岡 伸一 岡山大学大学院医歯薬学総合研究科 臨床遺伝子医療学
キーワード
非小細胞肺癌
導入療法
放射線化学療法
外科切除
備考
総説 (Reviews)
出版物タイトル
岡山医学会雑誌
発行日
2014-08-01
126巻
2号
出版者
岡山医学会
出版者(別表記)
Okayama Medical Association
開始ページ
103
終了ページ
107
ISSN
0030-1558
NCID
AN00032489
資料タイプ
学術雑誌論文
OAI-PMH Set
岡山大学
言語
Japanese
著作権者
Copyright (c) 2014 岡山医学会
論文のバージョン
publisher
査読
有り
DOI
NAID
Eprints Journal Name
joma
参考文献
1) Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB Jr, Lee JS, Dhingra H, De Caro L, Chasen M, McGavran M, et al. : A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst (1994) 86, 673-680.
2) Rosell R, Gómez-Codina J, Camps C, Maestre J, Padille J, Cantó A, Mate JL, Li S, Roig J, Olazábal A, et al. : A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med (1994) 330, 153-158.
3) Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT 3rd, Weick JK, Lonchyna VA, Presant CA, McKenna RJ, Gandara DR, et al. : Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages ⅢA (N2) and ⅢB non-small-cell lung cancer : mature results of Southwest Oncology Group phaseⅡstudy 8805. J Clin Oncol (1995) 13, 1880-1892.
4) Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, Fry WA, Darling G, et al. : Radiotherapy plus chemotherapy with or without surgical resection for stageⅢnon-small-cell lung cancer : a phase Ⅲrandomised controlled trial. Lancet (2009) 374, 379-386.
5) van Meerbeeck JP, Kramer GW, Van Schil PE, Legrand C, Smit EF, Schramel F, Tjan-Heijnen VC, Biesma B, Debruyne C, van Zandwijk N, Splinter TA, Giaccone G ; European Organisation for Research and Treatment of Cancer-Lung Cancer Group : Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage ⅢA-N2 non-small-cell lung cancer. J Natl Cancer Inst (2007) 99, 442-450.
6) Date H, Kiura K, Ueoka H, Tabata M, Aoe M, Andou A, Shibayama T, Shimizu N : Preoperative induction chemotherapy with cisplatin and irinotecan for pathological N(2) non-small cell lung cancer. Br J Cancer (2002) 86, 530-533.
7) Katayama H, Ueoka H, Kiura K, Tabata M, Kozuki T, Tanimoto M, Fujiwara T, Tanaka N, Date H, Aoe M, Shimizu N, Takemoto M, et al. : Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer. Br J Cancer (2004) 90, 979-984.
8) Toyooka S, Kiura K, Takemoto M, Oto T, Takigawa N, Fujiwara T, Miyoshi S, Date H : Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small-cell lung cancer with mediastinal lymph node metastasis. Interact Cardiovasc Thorac Surg (2012) 14, 565-569.
9) Toyooka S, Kiura K, Shien K, Katsui K, Hotta K, Kanazawa S, Date H, Miyoshi S : Induction chemoradiotherapy is superior to induction chemotherapy for the survival of non-small-cell lung cancer patients with pathological mediastinal lymph node metastasis. Interact Cardiovasc Thorac Surg (2012) 15, 954-960.
10) Shien K, Toyooka S, Kiura K, Matsuo K, Soh J, Yamane M, Oto T, Takemoto M, Date H, Miyoshi S : Induction chemoradiotherapy followed by surgical resection for clinical T3 or T4 locally advanced non-small cell lung cancer. Ann Surg Oncol (2012) 19, 2685-2692.
11) Felip E, Rosell R, Maestre JA, Rodríguez-Paniagua JM, Morán T, Astudillo J, Alonso G, Borro JM, González-Larriba JL, Torres A, Camps C, Guijarro R,et al. ; Spanish Lung Cancer Group : Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol (2010) 28, 3138-3145.
12) NSCLC Meta-analysis Collaborative Group : Preoperative chemotherapy for non-small cell lung cancer : a systematic review and meta-analysis of individual participant data. Lancet (2014) 383, 1561-1571.
13) Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Winton T, Johnson DH, Shulman L, Shepherd F, Deschamps C, Livingston RB, Gandara D : Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas : long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol (2007) 25, 313-318.
14) Kunitoh H, Kato H, Tsuboi M, Shibata T, Asamura H, Ichinose Y, Katakami N, Nagai K, Mitsudomi T, Matsumura A, Nakagawa K, Tada H, et al. ; Japan Clinical Oncology Group : PhaseⅡtrial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers : report of Japan Clinical Oncology Group trial 9806. J Clin Oncol (2008) 26, 644-649.
15) Toyooka S, Soh J, Oto T, Miyoshi S : Bronchoplasty to adjust mismatches in the proximal and distal bronchial stumps during bronchial sleeve resection of the left lower lobe and lingular division. Eur J Cardiothorac Surg (2013) 43, 182-183.
16) Toyooka S, Soh J, Shien K, Sugimoto S, Yamane M, Oto T, Date H, Miyoshi S : Sacrificing the pulmonary arterial branch to the spared lobe is a risk factor of bronchopleural fistula in sleeve lobectomy after chemoradiotherapy. Eur J Cardiothorac Surg (2013) 43, 568-572.
17) Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, et al. : Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 350, 2129-2139.
18) Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, et al. : EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy. Science (2004) 304, 1497-1500.
19) Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, et al. : Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 448, 561-566.
20) Cappuzzo F, Bemis L, Varella-Garcia M : HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med (2006) 354, 2619-2621.
21) Gautschi O, Pauli C, Strobel K, Hirschmann A, Printzen G, Aebi S, Diebold J : A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol (2012) 7, e23-24.
22) Shigematsu H, Gazdar AF : Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer (2006) 118, 257-262.
23) Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, Sakamoto H, Tsuta K, Furuta K, Shimada Y, Iwakawa R, Ogiwara H, et al. : KIF5B-RET fusions in lung adenocarcinoma. Nat Med (2012) 18, 375-377.
24) Hishida T, Nagai K, Mitsudomi T, Yokoi K, Kondo H, Horinouchi H, Akiyama H, Nagayasu T, Tsuboi M ; Japan Clinical Oncology G : Salvage surgery for advanced non-small cell lung cancer after response to gefitinib. J Thorac Cardiovasc Surg (2010) 140, e69-71.
25) Jaklitsch MT, Herndon JE 2nd, DeCamp MM Jr, Richards WG, Kumar P, Krasna MJ, Green MR, Sugarbaker DJ : Nodal downstaging predicts survival following induction chemotherapy for stage ⅢA (N2) non-small cell lung cancer in CALGB protocol #8935. J Surg Oncol (2006) 94, 599-606.
26) Shintani Y, Okimura A, Sato K, Nakagiri T, Kadota Y, Inoue M, Sawabata N, Minami M, Ikeda N, Kawahara K, Matsumoto T, Matsuura N, et al. : Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer. Ann Thorac Surg (2011) 92, 1794-1804 ; discussion 1804.
27) Shien K, Toyooka S, Ichimura K, Soh J, Furukawa M, Maki Y, Muraoka T, Tanaka N, Ueno T, Asano H, Tsukuda K, Yamane M, et al. : Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy. Lung Cancer (2012) 77, 162-167.